MyFinsight
Home
Blog
About
Contact
Download
Download image
Net increase
(decrease) in cash, cash...
-$5,918K
Prepaid expenses and
other current assets
-$15,672K
Stock-based compensation
expense
$6,199K
something is missing
$4,302K
Accounts receivable
-$3,167K
Non-cash lease expense
$636K
Depreciation expense
$403K
Proceeds from exercise of
stock options
$7K
Net cash provided by
(used in) operating...
-$3,529K
Net cash provided by
(used in) financing...
-$2,316K
Net cash used in
investing activities
-$73K
Canceled cashflow
$30,379K
Canceled cashflow
$7K
Net income (loss)
-$23,708K
Payment of direct
expenses associated with...
$2,323K
Purchase of property and
equipment
$73K
Accrued expenses and
other current...
-$5,218K
Current tax liability
-$4,147K
Right-of-use assets and
operating lease...
$572K
Deferred revenue
-$155K
Accounts payable
-$108K
Back
Back
Cash Flow
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)
source: myfinsight.com